Please assess the completion status of the following clinical trial:

Trial Title: Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of the breast, T2-T4 / T4a-c / N0-2 / M0, with positive estrogen and/or progesterone receptors. Patients with inflammatory breast cancer will not be included (Stage IIIb). Patients previously treated patients with no measurable disease or patients with metastatic disease will be excluded.~* Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice (see Appendix B - consent form).~* Females 60 years of age (postmenopausal).~* Be ambulatory (outpatient) and have an ECOG PS \<2 (Appendix F).~* Patients must have measurable disease by mammogram and/or breast ultrasound. The target lesion must not have been previously irradiated.~* No prior chemotherapy.~* Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \> 1,500/mm3, hemoglobin \> 8.0 g/dl, platelets \> 75,000/mm3, total bilirubin \< 2 mg/dl, serum creatinine \< 2 mg/dl, Transaminases (AST, ALT) may be up to 2.0 x institutional upper limit of normal. In addition \< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \< 1.0.~* No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy.~* Hypertension must be controlled (\<150/100 mmHg).~* Ejection Fraction \> 50%.~* No history of thrombosis during the previous year.~Exclusion Criteria:~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than this sponsor-investigator Bevacizumab cancer study.~* Uncontrolled high blood pressure (150/100 mmHg)~* Unstable angina~* New York Heart Association (NYHA) Grade II or greater congestive heart failure see Appendix G)~* History of myocardial infarction within 6 months~* History of stroke within 6 months~* Clinically significant peripheral vascular disease~* History of a bleeding disorder~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study~* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0~* Pregnant (positive pregnancy test) or lactating~* Urine protein: creatinine ratio 1.0 at screening. Patients demonstrating \> 1 gr of protein in 24 hr urine collection within 4 weeks prior to study entry will not participate in the trial.~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Serious, non-healing wound, ulcer, or bone fracture~* Unwilling or unable to comply with the protocol for the duration of the study.~* Psychiatric illness/social situations that would limit compliance with study requirements.~* History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.~* Patients with metastatic disease.

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete